QPPV.COM KNOWLEDGE ASSESSMENT

Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect

Test your understanding of the concepts covered by Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient has a laboratory-confirmed neutralising antibody but no documented clinical deterioration, hospitalisation, or other serious outcome. Which statement about seriousness is most appropriate?

A neutralising-antibody result is automatically a serious adverse reaction in every case A laboratory result alone does not automatically establish seriousness; seriousness should be assessed using the clinical outcome and applicable criteria The case cannot be processed until the patient develops clinical symptoms Any binding or neutralising antibody must be classified as fatal because death has been reported in another case

Question 2 of 10 A company has documented that safety materials were distributed to all intended recipients. What does this evidence demonstrate most directly?

That the risk has been clinically eliminated That distribution reached the intended recipients, but not necessarily that the risk was recognised or effectively managed That all patients received the recommended monitoring That the product's benefit-risk balance is favourable in every treated patient

Question 3 of 10 A source reports falling platelets, reduced ADAMTS13 activity, and a positive binding ADA test; no functional assay has been performed. Which case narrative is most appropriate?

“Neutralising antibodies caused treatment failure” “Treatment-emergent inhibitor confirmed; antibody origin established” “The reported clinical and laboratory findings are documented; binding ADA was detected, while neutralising activity has not been established” “No possible loss of efficacy because the antibody was only binding”

Question 4 of 10 Why should spontaneous report counts not be divided by estimated product use and presented as an incidence rate?

Spontaneous reports do not generally provide a reliable numerator or a suitably defined denominator for incidence estimation The product is a biologic, and incidence rates cannot be calculated for biologics Only binding-antibody reports can be counted in spontaneous-report systems Regulators prohibit any quantitative analysis of spontaneous reports

Question 5 of 10 A serious suspected cTTP exacerbation is reported, and inhibitor testing is pending. What should the pharmacovigilance team do?

Wait for the final assay result before processing or reporting the case Process and report the case according to applicable requirements using known facts, then follow up for pending results Record a negative inhibitor result until the laboratory confirms otherwise Close the case as non-serious because the mechanism is unconfirmed

Question 6 of 10 What is the significance of FDA requiring both a prospective interventional trial and a non-interventional real-world safety study?

The studies prove that rADAMTS13 caused every reported antibody-associated outcome They are intended to address evidence gaps that spontaneous reports alone cannot resolve, including immunogenicity, clinical loss of efficacy, and real-world follow-up They replace the need to process individual adverse-event reports They establish a universal antibody-testing interval for clinicians

Question 7 of 10 A report includes a suspected batch-related product complaint and a serious cTTP exacerbation. What is the appropriate organisational response?

Route the report only to quality and do not process it as a safety case Process the safety case and assess the product-quality concern through the relevant quality pathway in parallel where appropriate Assume a batch defect caused the antibody and close causality assessment Defer all action until quality confirms a manufacturing issue

Question 8 of 10 Which set of reports is most appropriate to combine as a single coherent clinical phenotype in aggregate signal review?

All reports with any detectable binding ADA, regardless of activity or outcome Reports of confirmed functional inhibition accompanied by reduced enzyme activity and compatible disease recurrence, assessed with assay and clinical context All reports of thrombocytopenia, regardless of diagnosis or treatment exposure All low activity results, even when sampling times and assay methods are unknown

Question 9 of 10 What limitation is especially relevant when applying the trial immunogenicity findings to patients who have never received plasma-based products?

All trial participants were plasma-naïve, so there is no evidence for previously exposed patients All trial participants had prior ADAMTS13 exposure through plasma-based products, and the label states that immunogenicity data are unavailable for plasma-naïve patients The trial measured only clinical outcomes and did not assess binding antibodies Prior plasma exposure proves that any later antibody was present before rADAMTS13 treatment

Question 10 of 10 The phase 3 study had very few acute TTP events in either treatment period. What conclusion about comparative acute-event prevention is most appropriate?

The small event count establishes that the treatments have identical effects The event count proves rADAMTS13 is ineffective The study supports clinical assessment but the sparse events do not establish a precise comparative effect on acute events The absence of acute events in one period proves that neutralising antibodies cannot occur

Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect

Cookie Settings